Publishing your work with Adis Adis Journal Title Impact Factor Timelines Medline Indexed Published Description Aim and Scope
American Journal of Cardiovascular Drugs 1.770 S:A 6-12 wks Yes Bi-Monthly Evaluations of all aspects of managing cardiovascular The American Journal of Cardiovascular Drugs promotes rational therapy & effective cardiology patient A:P 6-12 wks disorders including drugs, devices and other interventions. management by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer & established agents & procedures.
American Journal of Clinical Dermatology 1.708 S:A 6-12 wks Yes Bi-Monthly Evaluations of therapy in the management of The American Journal of Clinical Dermatology promotes rational therapy and effective dermatology A:P 6-12 wks dermatological disorders. patient management by providing a regular program of independent review articles covering all aspects of the management of dermatological conditions, particularly the place in therapy of newer and established agents and procedures.
Applied Health Economics & Health Policy n/a S:A 6-12 wks Yes Bi-Monthly Promotes the economic evaluation of all types of Applied Health Economics and Health Policy is an international peer reviewed journal that is primarily a A:P 6-12 wks healthcare interventions & policy initiatives, providing a vehicle for submitted papers on the economic implications of all types of healthcare interventions; economic practical economic background to healthcare decision consequences of policy initiatives; and analyses of pricing and reimbursement systems. The journal includes making. original research, reviews, editorials and correspondence.
BioDrugs 3.443 S:A 6-12 wks Yes Bi-Monthly Evaluations of biologics and molecularly targeted BioDrugs advances discussion and evaluation of the latest developments in the clinical application of A:P 6-12 wks therapeutics, including aspects of target selection, drug biotechnology for the treatment of human disease. development, and drug delivery.
Clinical Drug Investigation 1.822 S:A 6-8 wks Yes Monthly Rapid publication of original research covering all phases of Clinical Drug Investigation provides the rapid publication of original research covering all phases of clinical drug A:P 4-6 wks clinical drug development and therapeutic use of drugs development and therapeutic use of drugs.
Clinical Pharmacokinetics 5.398 S:A 6-12 wks Yes Monthly Evaluations of clinical pharmacokinetics to optimize drug Clinical Pharmacokinetics promotes continuing development of clinical pharmacokinetics and A:P 6-12 wks development and use. pharmacodynamics to improve drug therapy and to further postgraduate education in clinical pharmacology and therapeutics
CNS Drugs 4.795 S:A 6-12 wks Yes Monthly Evaluations of drug therapy in the management of CNS Drugs promotes the rationale pharmacotherapy and effective patient management within the disciplines of A:P 6-12 wks psychiatric and neurological disease. clinical psychiatry and neurology by providing a regular program of review articles covering important issues in the drug treatment of psychiatric and neurological disorders.
Drug Safety 3.634 S:A 6-12 wks Yes Monthly Expert opinion in pharmacovigilance, risk management, Drug Safety advances the rational use of pharmacotherapy by providing a program of review articles offering A:P 6-12 wks post-marketing surveillance, benefit-risk assessment and guidance for safe and effective drug utilization and prescribing. medication error prevention.
Drugs 4.226 S:A 6-12 wks Yes Three-Weekly Evaluations of drugs and drug therapy in patient Drugs promotes optimum pharmacotherapy by providing a program of review articles covering the most A:P 6-12 wks management. important aspects of clinical pharmacology and therapeutics.
Drugs & Aging 2.671 S:A 6-12 wks Yes Monthly Evaluations of drug therapy in older patients and diseases Drugs & Aging promotes optimum drug therapy in older adults through review articles covering the most A:P 6-12 wks of aging. important aspects of clinical pharmacology and patient management in this unique patient group. Physiological changes during aging that have implications for drug therapy also fall within the scope of the Journal.
High Blood Pressure & Cardiovascular n/a S:A 4-6 wks n/a Quarterly Official journal of the Italian Society of Hypertension High Blood Pressure & Cardiovascular Prevention promotes knowledge, updates and discussion in the field Prevention A:P 4-12 wks of hypertension and cardiovascular disease prevention, by providing a regular program of independent review articles covering key aspects of the management of hypertension and cardiovascular disease.
Molecular Diagnosis & Therapy 1.710 S:A 6-12 wks Yes Bi-Monthly Original research & timely reviews on the development, Molecular Diagnosis & Therapy provides insights into molecular diagnostic & pharmacogenomic techniques A:P 6-12 wks application & utilization of pharmacogenomics, biomarkers & their use in personalized medicine by linking diagnostic & prognostic biomarkers to appropriate therapy & & molecular diagnostics technologies. emphasizing the development of diagnostic/therapeutic products for use in drug development & therapeutic decision-making.
Pharmaceutical Medicine n/a S:A 6-12 wks No Bi-Monthly A multidisciplinary journal covering scientific and Pharmaceutical Medicine disseminates information by professionals working in pharma industry and related A:P 6-12 wks medical activities in discovery, development, evaluation, fields promoting the multidisciplinary specialty of pharmaceutical medicine, encompassing scientific/medically registration, monitoring & marketing of medicines. related activities in the discovery, development, evaluation, registration and monitoring of medicines.
Pediatric Drugs 1.786 S:A 6-12 wks Yes Bi-Monthly Evaluations of drug therapy in the pediatric population. Pediatric Drugs promotes the optimization and advancement of all aspects of pediatric pharmacotherapy A:P 6-12 wks and clinical pharmacology. Timely review articles provide healthcare decision makers the clinically applicable knowledge on issues relevant to drug therapy in all areas of neonatology and the care of children and adolescents.
PharmacoEconomics 2.663 S:A 6-12 wks Yes Monthly Applied pharmacoeconomics for optimal drug therapy and PharmacoEconomics promotes the continuing development and study of health economics, pharmacoeconomics A:P 6-12 wks health outcomes decision making. and quality-of-life assessment as applied to optimum drug therapy and health outcomes, providing a practical economic background to informed clinical prescribing decisions and allocation of healthcare resources.
Sports Medicine 5.155 S:A 6-12 wks Yes Monthly Reviews on current research and practice in sports Sports Medicine provides review articles that evaluate current literature to provide the rationale for application of A:P 6-12 wks medicine and exercise physiology. research findings in areas of sports medicine/sports science including performance research, sports related medical syndromes and the practical role that clinical medicine plays in sport, through injury prevention and treatment.
The Patient: Patient-Centered Outcomes 0.571 S:A 6-12 wks Yes Quarterly Patient-reported outcomes, quality of life, patient The Patient is a vehicle for the study of outcomes research to enhance therapy in a patient-centered manner. It A:P 6-12 wks empowerment, patient advocacy, health literacy, patient aims to examine the needs, values and role of the patient in an increasingly complex healthcare landscape in which compliance, risk communication, shared decision making. funding and decision making are requiring ever-greater awareness of the patients perspective.
Drugs in R&D TBD* S:A 6-12 wks Yes Quarterly Open Access and Online only journal featuring original “Drugs in R&D provides timely information on emerging drug classes and new treatments for specific disorders in A:P 6-12 wks research & reviews from all phases of clinical development an “”Open Access”” format for all to review. Healthcare decision makers are thus provided with clinically applicable including a strong link to clinical practice. knowledge about the likely place in therapy of a drug.”
*Not listed in 2011 & under review by Thomson; 2010 IF 1.707. Benefits of publishing with Adis
Adis is a well-established and respected global brand with over 40 years experience in translating research into clinical practice. Our portfolio features a wide range of high quality journals publishing current, objective research in biotechnology and personalized medicine, pharmacovigilance, health economics and outcomes research and specialized therapy areas, with a strong focus on clinical pharmacotherapy. Make sure that your research reaches the audience it deserves by placing it one of our prestigious titles. Here are some of the benefits you will get from publishing with Adis:
Peer review All of the Adis journals are peer reviewed externally by members of the international Editorial Boards and/or other specialists of equal repute.. This means that your research will be checked and verified as unbiased, scientifically accurate and clinically relevant by leading academics, making it a desirable reference for other researchers in the field.
Discoverability ✔ The majority of Adis journals boast enviable Impact Factors and are MEDLINE indexed, meaning that your article will be highly visible and easily located not only on our own platform but also via PubMed and other databases.
International audience Publication on the Adis/Springer platforms will expose your research to a wide and relevant international audience.
MEDLINE indexed Comprehensive support for authors A team of publication managers and editorial staff are on hand to guide you through the process from manuscript ✔ submission to publication, to ensure the accurate and timely publication of your research. Flexible publishing options Some titles may offer the option of rapid publishing or open access publishing, when this may be the most ✔ appropriate outlet for your research.
MEDLINE indexed Good Publishing Practice ✔ Adis journals endorse the ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals’, issued by the International Committee for Medical Journal Editors (ICMJE) and adhere to the Committee on Publication Ethics MEDLINE indexed (COPE) code of conduct for editors.
For more information MEDLINE indexed visit: http://bit.ly/AdisAuthor or email: [email protected]
Now part of